1,0
14. Okt. 2016
Mitarbeiter (anonym)
Ehemaliger Mitarbeiter
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Size and strength if they figure out what to do with it
Kontras
Almost everything, since management and the company as a whole, is run so poorly. The FDA is still pounding on Healthcare and RIFTS are common. They haven't released Spect or CT products from the FDA since 2011... yea 2011. The new CT is just a rebranded Brilliance.